Lipids & metabolic liver disease
Hepatic and serum branched‐chain fatty acid profile in patients with nonalcoholic fatty liver disease: A case–control study
Authors' conclusion
These results suggest that the increased production of liver BCFAs might be related to NAFLD development and progression.
Study context
- Population
- Patients with different stages of nonalcoholic fatty liver disease (NAFLD) defined by liver biopsy, and controls without NAFLD
- Participants
- 27 / 49 / 17
- Comparison
- NAFLD vs no NAFLD
- No NAFLDn = 27reference
- NAFLn = 49
- NASHn = 17
- Outcome
- Serum and hepatic BCFA profile (gas chromatography-mass spectrometry)
Methodological detailsbiopsy-defined NAFLD stages
- Biopsy-defined NAFLD stages
Main finding
As reported in the abstract
- Hepatic branched-chain fatty acids (BCFAs) significantly increased in NAFLD vs no NAFLD
- No differences in serum BCFAs between study groups
- Trimethyl BCFAs, iso-BCFAs and anteiso-BCFAs increased in NAFLD (NAFL or NASH) vs no NAFLD
Observational data: associations, not effects.
Further findings
Correlation of hepatic BCFAs
- Hepatic BCFAs related to histopathological diagnosis of NAFLD and other histological and biochemical parameters
Hepatic gene expression (real-time quantitative polymerase chain reaction (RT-qPCR))
- BCAT1, BCAT2 and BCKDHA mRNA upregulated in NAFLD
Original publication
Hepatic and serum branched‐chain fatty acid profile in patients with nonalcoholic fatty liver disease: A case–control study. Obesity (Silver Spring). Published 6 March 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →